Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The world’s largest clinical trial investigating treatments for COVID-19 has now launched in Ghana, West Africa. This is the sixth country to take part in RECOVERY, joining Indonesia, Nepal, South Africa, Vietnam, and the United Kingdom.

Aerial image of town in Ghana

Since March 2020, the RECOVERY Trial has discovered three effective treatments for COVID-19: the inexpensive steroid dexamethasonethe arthritis drug tocilizumab; and a monoclonal antibody treatment, now known as Ronapreve. However, as the pandemic continues to affect both high and lower income countries, and with the constant threat of new coronavirus variants, treatments are needed that are suitable for a wide range of patients and healthcare systems. Consequently, RECOVERY International was launched in February 2021.

Professor Sir Peter Horby, Joint Chief Investigator of RECOVERY, said: ‘I am thrilled to welcome Ghana to the RECOVERY endeavour to improve the care of patients with severe COVID-19. COVID-19 affects everyone, and we need treatments for everyone, wherever they are and whatever level of healthcare is available to them.’ 

In Ghana, RECOVERY will initially focus on whether using a higher dose of the anti-inflammatory treatment dexamethasone has an even greater effect than the standard doses of the drug previously shown to save lives by the RECOVERY trial. It is likely that empagliflozin, a routine treatment for type 2 diabetes, will also be added to the study in Ghana soon.

The first Ghanaian hospitals taking part in RECOVERY are the Ghana Infectious Disease Centre, Accra, and the Komfo Anokye Teaching Hospital, Kumasi. The study will be open to all hospital patients admitted with confirmed COVID-19. All participants will receive the usual care; some will additionally receive one of the treatments being investigated.

The expansion of RECOVERY International to Ghana is a partnership between the University of Oxford and the Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR).

The full story is available on the RECOVERY website

Similar stories

A new WWARN study supports safety of WHO recommended malaria treatment to advance elimination and reduce spread of artemisinin resistance

A new WWARN study, published in BMC Medicine, supports a World Health Organization (WHO) recommendation that a single primaquine target dose of 0.25 mg/kg is generally safe and well tolerated when given together with an ACT to treat malaria.

Routine surveillance data can provide an early warning system for antimalarial resistance in pre-elimination areas in Africa

In the first published study of its kind, a new WWARN paper in the Malaria Journal has created near-real-time maps to support antimalarial drug resistance monitoring, using routine malaria surveillance data and individually patient linked data on molecular markers of antimalarial drug resistance.

Oxford University launch new clinical trial to test a treatment for monkeypox

The team behind the world-leading RECOVERY trial of COVID-19 treatments are leading a new study investigating a potential treatment for people who have been diagnosed with monkeypox. The National Institute for Health and Care Research (NIHR) has commissioned and funded the study. The first patients have now been recruited.

Using mathematical modelling to fight malaria

Researchers have created a mathematical model to predict genetic resistance to antimalarial drugs in Africa to manage one of the biggest threats to global malarial control.

FORESFA and VIE project meetings

The Medicine Quality Research Group organised a multidisciplinary hybrid meeting at Keble College, Oxford, July 3 to 6, for the FORESFA project ‘Forensic epidemiology and impact of substandard and falsified antimicrobials on public health’, funded by a Wellcome Collaborative Award.

Incomplete reporting of COVID-19 disease severity criteria compromises meta-analysis

Patients affected by COVID-19 should be treated according to the severity of their disease. However, not all key national or international organisations define severity in the same way. This imprecision in severity assessment compromises the validity of some therapeutic recommendations. Using individual patient data would better guide and improve therapeutic recommendations for COVID-19.